Effect of caffeine intake 12 or 24 hours prior to melatonin intake and CYP1A2*1F polymorphism on CYP1A2 phenotyping by melatonin
- PMID: 17040215
- DOI: 10.1111/j.1742-7843.2006.pto_491.x
Effect of caffeine intake 12 or 24 hours prior to melatonin intake and CYP1A2*1F polymorphism on CYP1A2 phenotyping by melatonin
Abstract
Earlier evidence suggests that melatonin is almost exclusively metabolised by CYP1A2 and could serve as a probe drug for CYP1A2 phenotyping. However, caffeine inhibits the metabolism of melatonin by CYP1A2 and dietary caffeine could be a potential confounder for the measurement of CYP1A2 activity with melatonin. We undertook a 3-phase cross-over study in 12 healthy volunteers to examine whether caffeine (200 mg single dose), taken 12 hr or 24 hr prior to melatonin intake, would affect the results of CYP1A2 phenotyping results as assessed by a spot sample melatonin concentration 1.5 hr after intake of 6 mg of melatonin orally. In addition we examined the influence of the CYP1A2*1F polymorphism on the phenotyping results by combining the present material with another 12 persons from a previous study. Caffeine, co-administered 12 or 24 hr prior to melatonin intake, did not have any significant effect on the 1.5 hr melatonin concentration (P=0.086 for ANOVA), but in two volunteers about 4 times increase in melatonin concentration was observed after caffeine intake 12 hr (but not 24 hr) before phenotyping with melatonin. Also, individuals homozygous for the CYP1A2*1A allele had clearly higher 1.5 hr melatonin concentration compared with the *1F/*1F or the *1F/*1A genotypes. Abstinence from caffeine for 24 hr prior to melatonin intake should be enough to overcome the possible confounding effect of caffeine on the CYP1A2 phenotyping with melatonin. Also, melatonin may be a sensitive probe to detect phenotypic differences with regard to CYP1A2*1F polymorphism. Melatonin might be, thus, advantageous for CYP1A2 phenotyping compared to the standard probe caffeine.
Similar articles
-
Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: a pilot study.Clin Pharmacol Ther. 2001 Jul;70(1):10-6. doi: 10.1067/mcp.2001.116512. Clin Pharmacol Ther. 2001. PMID: 11452239
-
The effect of oral contraceptives on the pharmacokinetics of melatonin in healthy subjects with CYP1A2 g.-163C>A polymorphism.J Clin Pharmacol. 2008 Aug;48(8):986-94. doi: 10.1177/0091270008318669. Epub 2008 May 19. J Clin Pharmacol. 2008. PMID: 18490497
-
Assessment of CYP1A2 activity in clinical practice: why, how, and when?Basic Clin Pharmacol Toxicol. 2005 Sep;97(3):125-34. doi: 10.1111/j.1742-7843.2005.pto_973160.x. Basic Clin Pharmacol Toxicol. 2005. PMID: 16128905 Review.
-
Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity.Br J Clin Pharmacol. 2003 Dec;56(6):679-82. doi: 10.1046/j.1365-2125.2003.01933.x. Br J Clin Pharmacol. 2003. PMID: 14616429 Free PMC article. Clinical Trial.
-
[On the possibility of patient phenotyping on the basis of cytochrome p-450 1A2 isoenzyme activity using caffeine as the test substrate].Eksp Klin Farmakol. 2009 Sep-Oct;72(5):61-5. Eksp Klin Farmakol. 2009. PMID: 19928580 Review. Russian.
Cited by
-
Evaluation of CYP1A2 activity: Relationship between the endogenous urinary 6-hydroxymelatonin to melatonin ratio and paraxanthine to caffeine ratio in dried blood spots.Clin Transl Sci. 2022 Jun;15(6):1482-1491. doi: 10.1111/cts.13263. Epub 2022 Mar 26. Clin Transl Sci. 2022. PMID: 35338582 Free PMC article.
-
Where Failure Is Not an Option -Personalized Medicine in Astronauts.PLoS One. 2015 Oct 21;10(10):e0140764. doi: 10.1371/journal.pone.0140764. eCollection 2015. PLoS One. 2015. PMID: 26489089 Free PMC article.
-
Pharmacokinetic and pharmacodynamic herb-drug interactions-part I. Herbal medicines of the central nervous system.PeerJ. 2023 Nov 15;11:e16149. doi: 10.7717/peerj.16149. eCollection 2023. PeerJ. 2023. PMID: 38025741 Free PMC article. Review.
-
Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2.AAPS J. 2009 Sep;11(3):481-94. doi: 10.1208/s12248-009-9127-y. Epub 2009 Jul 10. AAPS J. 2009. PMID: 19590965 Free PMC article. Review.
-
Circadian disruption and cancer- and treatment-related symptoms.Front Oncol. 2022 Oct 28;12:1009064. doi: 10.3389/fonc.2022.1009064. eCollection 2022. Front Oncol. 2022. PMID: 36387255 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical